Neurogene Inc. (NASDAQ:NGNE) Shares Purchased by Barclays PLC

Barclays PLC raised its stake in Neurogene Inc. (NASDAQ:NGNE) by 319.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,859 shares of the company’s stock after acquiring an additional 11,316 shares during the quarter. Barclays PLC owned approximately 0.11% of Neurogene worth $623,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of NGNE. Bank of New York Mellon Corp purchased a new position in shares of Neurogene during the 2nd quarter valued at approximately $1,107,000. Rhumbline Advisers purchased a new position in Neurogene in the second quarter valued at $491,000. Quest Partners LLC acquired a new position in shares of Neurogene in the second quarter worth about $55,000. Avoro Capital Advisors LLC purchased a new stake in shares of Neurogene during the 2nd quarter worth about $802,000. Finally, Integral Health Asset Management LLC acquired a new stake in shares of Neurogene during the 2nd quarter valued at about $2,547,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NGNE. Leerink Partners upped their price target on Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, November 12th. William Blair reiterated an “outperform” rating on shares of Neurogene in a research report on Tuesday, November 19th. BMO Capital Markets dropped their price target on shares of Neurogene from $60.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. Stifel Nicolaus upped their price objective on shares of Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Neurogene in a research report on Monday, November 25th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $60.83.

Neurogene Stock Up 2.6 %

Neurogene stock opened at $22.86 on Thursday. The company has a fifty day simple moving average of $32.43 and a 200-day simple moving average of $37.32. Neurogene Inc. has a 52-week low of $14.44 and a 52-week high of $74.49.

Insider Activity at Neurogene

In other news, CEO Rachel Mcminn purchased 47,500 shares of the stock in a transaction dated Friday, November 22nd. The shares were purchased at an average price of $20.40 per share, with a total value of $969,000.00. Following the transaction, the chief executive officer now owns 1,297,859 shares in the company, valued at $26,476,323.60. The trade was a 3.80 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christine Mikail Cvijic acquired 24,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were purchased at an average price of $20.48 per share, with a total value of $491,520.00. Following the completion of the transaction, the chief financial officer now owns 76,844 shares of the company’s stock, valued at $1,573,765.12. The trade was a 45.42 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 120,270 shares of company stock valued at $2,720,249. Corporate insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.